hierridin B: isolated from Phormidium ectocarpi; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 10021709 |
| CHEMBL ID | 4548932 |
| SCHEMBL ID | 21558842 |
| MeSH ID | M0300414 |
| Synonym |
|---|
| hierridin b |
| SCHEMBL21558842 |
| 2,4-dimethoxy-6-pentadecylphenol |
| CHEMBL4548932 |
| DTXSID601047750 |
Hierridin B is a potential anticancer compound that targets mitochondrial activity and function.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Hierridin B is a potential anticancer compound that targets mitochondrial activity and function." | ( Hierridin B Isolated from a Marine Cyanobacterium Alters VDAC1, Mitochondrial Activity, and Cell Cycle Genes on HT-29 Colon Adenocarcinoma Cells. Costa, M; Freitas, S; Leão, PN; Martins, R; Urbatzka, R; Vasconcelos, V; Vitorino, R, 2016) | 3.32 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1537331 | Antimalarial activity against Plasmodium falciparum Dd2 infected in human erythrocytes after 48 hrs by SYBR Green-1 dye based assay | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Structure of Hierridin C, Synthesis of Hierridins B and C, and Evidence for Prevalent Alkylresorcinol Biosynthesis in Picocyanobacteria. |
| AID1537330 | Antimalarial activity against Plasmodium falciparum 3D7 infected in human erythrocytes after 48 hrs by SYBR Green-1 dye based assay | 2019 | Journal of natural products, 02-22, Volume: 82, Issue:2 | Structure of Hierridin C, Synthesis of Hierridins B and C, and Evidence for Prevalent Alkylresorcinol Biosynthesis in Picocyanobacteria. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||